Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $10.5714.

PSNL has been the subject of a number of analyst reports. Guggenheim lifted their target price on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Morgan Stanley upped their price objective on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. BTIG Research raised their target price on Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Needham & Company LLC boosted their price target on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Sunday, December 14th.

Insider Activity at Personalis

In other news, CFO Aaron Tachibana sold 103,668 shares of Personalis stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the transaction, the chief financial officer owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher M. Hall sold 29,612 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently added to or reduced their stakes in PSNL. Legal & General Group Plc acquired a new position in Personalis in the 2nd quarter valued at approximately $30,000. Ameritas Investment Partners Inc. bought a new stake in shares of Personalis during the second quarter valued at approximately $34,000. BNP Paribas Financial Markets raised its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Focus Partners Wealth bought a new position in Personalis in the first quarter worth $47,000. Finally, Alpha Wealth Funds LLC acquired a new stake in Personalis during the second quarter worth $66,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Trading Down 1.1%

Shares of NASDAQ:PSNL opened at $8.33 on Friday. The firm has a market cap of $739.70 million, a price-to-earnings ratio of -9.47 and a beta of 1.99. Personalis has a 1 year low of $2.83 and a 1 year high of $11.40. The business has a fifty day simple moving average of $9.00 and a 200 day simple moving average of $7.10.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. The company had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. On average, sell-side analysts forecast that Personalis will post -1.4 EPS for the current year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.